Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra TherapeuticsZVRA -1.22%69 PS Ratio is 4.92 as of Aug. 13, 2026, which is 24% below its 10-year median of 6.44. GuruFocus rates ZVRA with a GF Score™ of 69/100 and a GF Value™ of $20.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Zevra Therapeutics ranks better than 67.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zevra Therapeutics's share price is $11.30.
Zevra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $2.30. Hence, Zevra Therapeutics's PS Ratio for today is 4.92.
The historical rank and industry rank for Zevra Therapeutics's PS Ratio or its related term are showing as below:
ZVRA'
s PS Ratio Range Over the Past 10 Years
Min: 0.38 Med: 6.44 Max: 23.09
Current: 4.92
During the past 13 years, Zevra Therapeutics's highest PS Ratio was 23.09. The lowest was 0.38. And the median was 6.44.
ZVRA's PS Ratio is ranked better than 67.45% of 931
companies
in the Biotechnology industry
Industry Median: 9.58
vs ZVRA: 4.92
Zevra Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Zevra Therapeutics was 101.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 84.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -10.50% per year.
During the past 13 years, Zevra Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 84.70% per year. The lowest was -65.10% per year. And the median was -28.75% per year.
Zevra Therapeutics (NAS:ZVRA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zevra Therapeutics PS Ratio Related Terms
Zevra Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zevra Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zevra Therapeutics's Share Price of today is $11.30. Zevra Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zevra Therapeutics (ZVRA) has a PS Ratio of 4.92 as of Aug. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zevra Therapeutics and its competitors. This is 24% below median its historical median of 6.44. Over the past decade, Zevra Therapeutics' PS Ratio has ranged from 0.38 to 23.09. According to the industry distribution chart, Zevra Therapeutics ranks #303 out of 931 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Zevra Therapeutics' PS Ratio too high?
Zevra Therapeutics' current PS Ratio of 4.92 is 24% below median its 10-year median of 6.44. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 23.09. The Biotechnology industry median PS Ratio is 9.58. Zevra Therapeutics' value of 4.92 is 48.6% below this industry median. Based on the distribution chart, Zevra Therapeutics ranks #303 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' PS Ratio compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #303 out of 931 companies for PS Ratio. This puts Zevra Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.58. Zevra Therapeutics' value of 4.92 is 48.6% below this benchmark. Historically, Zevra Therapeutics' own PS Ratio has ranged from 0.38 to 23.09 over the past decade. While the company's 10-year median is 6.44 vs. the industry median of 9.58, Zevra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.58, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current PS Ratio of 4.92 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current PS Ratio is 4.92, which is 24% below median its own 10-year median of 6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $20.92, compared to a current price of $11.30 — trading 46% below its estimated fair value. The current PS Ratio is 4.92, which is 24% below median its 10-year median of 6.44 and 48.6% below the Biotechnology industry median of 9.58. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current PS Ratio is 4.92 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $11.30 is trading 46% below its estimated GF Value™ of $20.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
PS Ratio: 4.92 (24% below median its 10-year median of 6.44)
GF Value™: $20.92 vs. price of $11.30 (46% below fair value)
Industry Position: 48.6% below the Biotechnology median (#303 of 931)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for ZVRA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
